The results appear July 2 in the journal"We hope that this proof-of-concept study is the first of many applications of engineered plasma B cells, and eventually will lead to a single-shot therapeutic," says senior study author Richard James of the Seattle Children's Research Institute."Because engineered plasma B cells can live for a very long time, greater than 10 years, they could be used as a long-term source of many biologic drugs.
"We think that the first application of engineered plasma B cells will be to produce drugs that are difficult for patients to use," James says."In this study, we wanted to demonstrate proof of concept and efficacy for engineered B cell therapies." Based on the results, the researchers propose that ePC strategies could increase the functional half-life of bispecifics in patients with acute leukemias and other diseases where treatment half-life is limiting or where plasma cell local delivery could enhance therapeutic efficacy.
As noted by the authors, further studies in humanized mice and non-human primates are warranted to fully understand the activity, longevity, and tissue localization of ePCs."In the short term, we plan to test whether engineered plasma B cells that produce bispecific antibodies are effective in other B cell-mediated diseases, including autoimmunity. These tests will initially be conducted in animal models.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: physorg_com - 🏆 388. / 55 Read more »